Dottorato in Medicina Molecolare

1. “Basic fibroblast growth factor and vascular endothelial growth factor serum  levels in breast cancer patients and healthy women: useful as diagnostic tools?”Granato AM, Nanni O, Falcini F, Folli S, Mosconi G, De Paola F, Medri L, Amadori D, Volpi A. Breast Cancer Res. Dic 2004 IF:3.0

2. “Do Serum Angiogenic Growth Factors Provide Additional Information to  that of Conventional Markers in Monitoring  the Course of Metastatic Breast Cancer?”. Anna Maria Granato, Giovanni Luca Frassineti, Noemi Giovannini, Michela Ballardini, Oriana Nanni, Roberta Maltoni, Dino Amadori,  Annalisa Volpi Tumor biology Nov 2006 IF:2.3

 3. “HER-2 expression and cell proliferation: prognostic markers in patients with node-negative breast cancer”. Volpi A, Nanni O, De Paola F,Granato AM,  Mangia A, Monti F, Schittulli F, De Lena M,  Scarpi E, Rosetti P, Monti M, Gianni L, Amadori D, Paradiso A. J Clin Oncol. Lug 2003 IF:9.8

 4. “p27/kip1 expression in normal epithelium, benign and neoplastic breast lesions”De Paola F, Vecci AM, Granato AM, Liverani M, Monti F, Innoceta AM, Gianni  L,Saragoni L, Ricci M, Falcini F, Amadori D, Volpi A.J Pathol. Gen 2002  IF:5.3

5. “Vascular endothelial growth factor and prognosis in patients with node-negative breast cancer”De Paola F, Granato AM, Scarpi E, Monti F, Medri L, Bianchi S,   Amadori D, Volpi Int J Cancer Mar 2002 IF:4,4

 6. “Restored T-cell activation mechanisms in human tumour-infiltrating lymphocytes from melanomas and colorectal carcinomas after exposure to interleukin-2” De Paola F, Ridolfi R, Riccobon A, Flamini E, Barzanti F, Granato AM, Mordenti GL, Medri L, Vitali P, Amadori D. Br J Cancer Gen 2003 IF:3.7

 7. “Role of biological markers in the clinical outcome of colon cancer” Nanni O, Volpi A, Frassineti GL, De Paola F, Granato AM, Dubini A, Zoli W, Scarpi E, Turci D, Oliverio G, Gambi A, Amadori D. Br J Cancer Ott 2002  IF:3.7

 8.  “Biomarker prediction of clinical outcome in operable breast cancer patients treated with tamoxifen” Scarpi E, De Paola F, Sarti M, Bajorko P, Granato AM, Volpi A, Nanni O, Maltoni R, Amadori D. Breast Cancer Res Treat. Lug 2001 IF:3.3

 9. “Prognostic significance of biologic markers in node-negative breast cancer patients: a prospective study” Volpi A, De Paola F, Nanni O, Granato AM, Bajorko P, Becciolini A, Scarpi E, Riccobon A, Balzi M, Amadori D. Breast Cancer Res Treat. Lug 2000 IF:3.3 

10. “Modulation of Drug Cytotoxicity by Iressa (ZD1839) in Pancreatic Cancer Cell Lines” Rosetti M, Tesei A, Ulivi P, Fabbri F, Vannini I, Brigliadori G, Granato AM, Amadori D, Zoli W. Cancer Biol Ther. Ott 2005 IF: 3.3

 11. “Immunosuppression in renal cancer: differential expression of signal transduction molecules in tumor-infiltrating, near-tumor tissue, and peripheral    blood lymphocytes”. Riccobon A, Gunelli R, Ridolfi R, De Paola F, Flamini E, Fiori M, Saltutti C, Petrini M, Fiammenghi L,  Stefanelli M, Granato AM, Cuzzocrea DE, Amadori D. Cancer Invest. 2004  IF:1.9   

 12.“Iressa Strengthens the Cytotoxic Effect of Docetaxel in NSCLC Models that Harbor Specific Molecular Characteristics”. Rosetti M, Zoli W, Tesei A, Ulivi P, Fabbri F, Vannini I,   Brigliadori G, Granato AM,  Amadori D,  Silvestrini R. Journal of Cellular Physiology 2007  IF: 4,4

 13. “Breast cancer: biomorphological prognostic factor”Saragoni A, Medri L, Bacci F, Dubini A, Gaudio M,  Padovani    F, Saragoni L, De Paola F, Granato AM  European Journal of Oncology 2001

 14.  “Valutazione analitica di CEA e AFP con il sistema Technicon Immuno  Bayer”Nunziatini R, Pallotti G,Granato AM  Ligand Assay”(Vol.1 n.1 1996)

15. “Valutazione analitica del sistema Cobas Core Roche per la diagnostica      tiroidea”. Nunziatini R, Granato AM, Pallotti G Ligand Quarterly”(Vol 13 n° 2 1994)

 16. “Urine telomerase activity for the detection of bladder cancer in females,”  S. Bravaccini, M.A. Sanchini, A.M. Granato, R. Gunelli, O. Nanni, D. Amadori, D. Calistri, R. Silvestrini. J of Urology  2007 IF: 3.71

 17.  “Unexpected high response rate to traditional therapy after dendritic cell-based vaccine in advanced melanoma: update of clinical outcome and subgroup analysis”. Ridolfi L, Petrini M, Fiammenghi L, Granato AM, Ancarani V, Pancisi E, Scarpi E, Guidoboni M, Migliori G, Sanna S, Tauceri F, Verdecchia GM, Riccobon A, Ridolfi R. Clin Dev Immunol. 2010;2010:504979.

 18.   “FRET microscopy autologous tumor lysate processing in mature dendritic cell vaccine therapy”. Fiammenghi L, Ancarani V, Rosales T, Knutson JR, Petrini M, Granato AM,  Pancisi E, Ridolfi L, Ridolfi R, Riccobon A, Neyroz P. J Transl Med. 2010 Jun 3;8:52.

 19.” Tumor endothelial marker 8 expression levels in dendritic cell-based cancer vaccines are related to clinical outcome. Venanzi FM, Petrini M, Fiammenghi  L,Bolli E, Granato AM, Ridolfi L, Gabrielli F,Barucca A, Concetti A, Ridolfi R, Riccobon A. Cancer Immunol Immunother. 2010 Jan;59(1):27-34. Epub 2009 May 7.

 20.  “Isolation of stem/progenitor cells from normal lung tissue of adult humans”.Tesei A, Zoli W, Arienti C, Storci G, Granato AM, Pasquinelli G, Valente S, Orrico C, Rosetti M, Vannini I, Dubini A, Dell'Amore D, Amadori D, Bonafè M. Cell Prolif. 2009 Jun;42(3):298-308.

 21.  “Dendritic cell-based vaccine in advanced melanoma: update of clinical  outcome” Ridolfi L, Petrini M, Fiammenghi L, Granato AM, Ancarani V, Pancisi E, Brolli C, Selva M, Scarpi E, Valmorri L, Nicoletti SV, Guidoboni M, Riccobon A, Ridolfi R. Melanoma Res. 2011 Dec;21(6):524-9.

 

2011, 10 mesi presso l'Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Forlì